维格列汀对大鼠脊髓损伤后神经细胞凋亡及运动功能恢复的影响

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (1525 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To investigate the effect of Vildagliptin (Vilda) on locomotor function recovery and neural cell apotosis in a rat model of spinal cord injury. Methods: Forty-eight SD rats were randomly divided into 3 groups (n=16): the Sham group, the SCI group and the SCI+Vilad group. Clip compression SCI model was established as previously described. The SCI+Vilad group was treated with Vilad at a dose of 10 mg·kg-1·d-1 by gavage for 7 days in a row, then once every 3 days; the SCI group was treated with the same dosage of normal saline. The Basso-Beattie-Bresnahan (BBB) score was obtained at 1, 3, 7, 14, 21, 28 d after operation. Immunofluorescence staining and Western blot were used to detect the expression of apoptotic related proteins expression (Bcl-2, Bax, Cleaved Caspase 3) at 3 d after operation. Nissl staining was performed at 7 d after operation to detect the surviving neurons. At 28 d, the, the footprint analysis was used to assess the locomotor recovery. Results: Compared with the Sham group, SCI group showed significantly lower BBB scores and inconsistent footprints; the number of VMNs was decreased significantly. Immunofluorescence staining and western blot results showed enhanced expression of apoptotic related proteins (Bax, Cleaved Caspase 3), but the expression of anti-apoptotic related protein (Bcl-2) was decreased (P<0.05). Compared with the SCI group, the rats in SCI+Vilda group got higher BBB scores, more consistent footprints; the number of VMNs was also increased. At the same time, the expression of apoptotic related proteins (Bax, Cleaved Caspase 3) was decreased significantly and the expression of anti-apoptotic related protein (Bcl-2) was increased obviously (P<0.05). Conclusion: All of these findings indicated that Vildagliptin shows neuroprotective effect after SCI in rats via inhibiting the VMNs apoptosis, and finally promotes the locomotor recovery.

Key words： spinal cord injury vildagliptin apoptosis locomotor revovery rats

Received: 10 December 2018

	Service
	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	XU Tianzhen
	WANG Chenjian
	TANG Chengxuan

URL:

https://xb.wmu.edu.cn/EN/ OR https://xb.wmu.edu.cn/EN/Y2019/V49/I7/523

[1] RAMER L, RAMER M S, BRADBURY E J. Restoring function after spinal cord injury: towards clinical translation of experimental strategies[J]. Lancet Neurol, 2014, 13(12): 1241-1256.
[2] VALENZUELA V, ONATE M, HETZ C, et al. Injury to the nervous system: A look into the ER[J]. Brain Res, 2016, 1648(Pt B): 617-625
[3] CROWE M, BRESNAHAN J, SHUMAN S, et al. Apoptosis and delayed degeneration after spinal cord injury in rats and monkeys[J]. Nat Med, 1997, 3(1): 73-76
[4] NARANG A, QIAO F, ATKINSON C, et al. Natural IgM antibodies that bind neoepitopes exposed as a result of spinal cord injury, drive secondary injury by activating com-plement[J]. J Neuroinflammation, 2017, 14(1): 120.
[5] BEATTIE M, FAROOQUI A, BRESNAHAN. J Review of current evidence for apoptosis after spinal cord injury[J]. J Neurotrauma, 2000, 17(10): 915-925.
[6] THURET S, MOON L, GAGE F. Therapeutic interventions after spinal cord injury[J]. Nat Rev Neurosci, 2006, 7(8): 628-643.
[7] KEATING G M. Vildagliptin: a review of its use in type 2 diabetes mellitus[J]. Drugs, 2014, 74(5): 587-610.
[8] SA-NGUANMOO P, TANAJAK P, KERDPHOO S, et al. SGLT2-inhibitor and DPP-4 inhibitor improve brain function via attenuating mitochondrial dysfunction, insulin resistance, inflammation, and apoptosis in HFD-induced obese rats[J]. Toxicol Appl Pharmacol, 2017, 333: 43-50
[9] AVILA DDE L, ARAUJO G R, SILVA M, et al. Vildagliptin ameliorates oxidative stress and pancreatic beta cell destruction in type 1 diabetic rats[J]. Arch Med Res, 2013, 44(3): 194-202.
[10] MA Q H, JIANG L F, MAO J L, et al. Vildagliptin prevents cognitive deficits and neuronal apoptosis in a rat model of Alzheimer’s disease[J]. Mol Med Rep, 2018, 17(3): 4113-4119.
[11] ABDELSALAM R M, SAFAR M M. Neuroprotective effects of vildagliptin in rat rotenone Parkinson’s disease model: role of RAGE-NFkappaB and Nrf2-antioxidant signaling pathways[J]. J Neurochem, 2015, 133(5): 700-707.
[12] MARQUES S A, GARCEZ V F, DEL BEL E A, et al. A simple, inexpensive and easily reproducible model of spinal cord injury in mice: morphological and functional assess-ment[J]. J Neurosci Methods, 2009, 177(1): 183-193.
[13] CHERIYAN T, RYAN D J, WEINREB J H, et al. Spinal cord injury models: a review[J]. Spinal Cord, 2014, 52(8): 588-595.
[14] HE Z L, ZHOU Y L, HUANG Y, et al. Dl-3-n-butylphthalide improves functional recovery in rats with spinal cord injury by inhibiting endoplasmic reticulum stress-induced apopto-sis[J]. Am J Transl Res, 2017, 9(3): 1075-1087.
[15] BASSO D M, BEATTIE M S, BRESNAHAN J C. A sensitive and reliable locomotor rating scale for open field testing in rats[J]. J Neurotrauma, 1995, 12(1): 1-21.
[16] WU F, WEI X, WU Y, et al. Chloroquine promotes the recovery of acute spinal cord injury by inhibiting autophagy-associated inflammation and endoplasmic reticulum stress [J]. J Neurotrauma, 2018, 35(12): 1329-1344.
[17] STIRLING D P, KHODARAHMI K, LIU J, et al. Minocycline treatment reduces delayed oligodendrocyte death, attenuates axonal dieback, and improves functional outcome after spinal cord injury[J]. J Neurosci, 2004, 24(9): 2182-2190.
[18] KJELL J, OLSON L. Rat models of spinal cord injury: from pathology to potential therapies[J]. Dis Model Mech, 2016, 9(10): 1125-1137.
[19] MCDONALD J W, SADOWSKY C. Spinal-cord injury[J]. Lancet, 2002, 359(9304): 417-425.
[20] GRUMBLES R M, THOMAS C K. Motoneuron death after human spinal cord injury[J]. J Neurotrauma, 2017, 34(3): 581-590.
[21] KWON B K, TETZLAFF W, GRAUER J N, et al. Pathophysiology and pharmacologic treatment of acute spinal cord injury[J]. Spine J, 2004, 4(4): 451-464.
[22] Ahuja C S, Wilson J R, Nori S, et al. Traumatic spinal cord injury[J]. Nat Rev Dis Primers, 2017, 3: 17018.
[23] WILSON J R, FORGIONE N, FEHLINGS M G. Emerging therapies for acute traumatic spinal cord injury[J].CMAJ, 2013,185(6):485-492.
[24] ANILKUMAR U, PREHN J H. Anti-apoptotic BCL-2 family proteins in acute neural injury[J]. Front Cell Neurosci, 2014 ,8:281.
[25] KIRKLAND R A, FRANKLIN J L. Bax, reactive oxygen, and cytochrome c release in neuronal apoptosis[J]. Antioxid Redox Signal, 2003, 5(5): 589-596.
[26] HYMAN B T, YUAN J. Apoptotic and non-apoptotic roles of caspases in neuronal physiology and pathophysiology[J].Nat Rev Neurosci, 2012, 13(6): 395-406.